알레르기 진단 시장 : 검사 유형별, 기술, 검체 유형별, 알레르겐 유형별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Allergy Diagnostics Market is projected to grow by USD 9.86 billion at a CAGR of 6.61% by 2032.

Allergy Diagnostics Executive Summary

The allergy diagnostics market is becoming a core pillar of precision medicine as allergic rhinitis, asthma, food allergy, atopic dermatitis, drug allergy, and insect venom hypersensitivity continue to rise worldwide. The World Allergy Organization reports that allergic diseases affect an estimated 10% to 40% of the global population, while the World Health Organization estimated 262 million people lived with asthma in 2019, underscoring sustained demand for accurate allergy testing and long-term disease management.

Clinical adoption is shifting from broad symptom-based assessment toward evidence-based diagnosis using skin prick testing, serum-specific IgE testing, component-resolved diagnostics, multiplex immunoassays, and digital decision support. For manufacturers, laboratories, health systems, and payers, growth is tied to faster turnaround times, validated biomarkers, guideline-aligned testing, and improved access across high-burden pediatric and adult populations.

Transformative Shifts in Allergy Diagnostics

The allergy diagnostics landscape is being reshaped by three major shifts: the move from extract-based testing to molecular allergy diagnostics, the expansion of automated immunoassay platforms, and the growing clinical expectation for test results that guide treatment decisions rather than simply confirm sensitization. Component-resolved diagnostics are especially important for differentiating genuine food allergy risk from cross-reactivity, which can help reduce unnecessary avoidance diets and improve allergen immunotherapy selection.

A second transformation is occurring in care delivery. Allergy testing is expanding beyond specialist clinics into hospital laboratories, primary care networks, retail-linked diagnostics, and telehealth-supported pathways. This trend is supported by increasing awareness of asthma-allergy comorbidity, food allergy safety, and the need for early diagnosis in children, but it also raises the bar for quality control, clinician education, and reimbursement clarity.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence allergy diagnostics through pattern recognition, clinical risk stratification, laboratory workflow optimization, and interpretation support for multiplex IgE panels. AI-enabled tools can help clinicians connect symptoms, exposure history, total IgE, specific IgE, eosinophil counts, spirometry, and comorbidity data to improve diagnostic confidence, particularly where specialist access is limited.

The cumulative impact of AI will depend on validation, explainability, and regulatory oversight. Industry leaders should prioritize clinically governed AI that improves sensitivity, specificity, and turnaround time without overdiagnosis. The strongest opportunities are expected in triage algorithms, automated assay quality monitoring, population-level allergy surveillance, and decision support for immunotherapy eligibility.

Key Regional Insights for Allergy Diagnostics

Asia-Pacific is one of the most dynamic regions for allergy diagnostics, supported by urbanization, air pollution exposure, rising middle-class healthcare spending, and expanding laboratory infrastructure in China, India, Japan, South Korea, and Australia. North America remains a high-value region driven by strong clinical awareness, established reimbursement pathways, regulated diagnostic innovation, and the documented allergy burden reported by the CDC, including seasonal and food allergies in children and adults.

Europe benefits from guideline-driven care, extensive specialist networks, and active research communities, particularly in Germany, France, Italy, Spain, and the United Kingdom. Latin America is advancing through private laboratory networks and growing asthma and rhinitis management programs, while the Middle East is seeing demand linked to dust exposure, indoor allergens, and investment in tertiary care. Africa remains underpenetrated, with progress dependent on affordable testing, workforce training, and integration with respiratory disease programs.

Key Group Insights Across Major Economic Blocs

ASEAN markets are gaining relevance as expanding urban populations and private diagnostic chains increase access to allergy testing, although affordability and specialist availability remain uneven. GCC countries are investing in advanced hospital systems and laboratory automation, creating demand for high-throughput immunoassay platforms and allergy panels suited to indoor, dust mite, mold, and environmental allergen profiles.

The European Union is defined by harmonized regulatory expectations, strong evidence standards, and growing adoption of molecular diagnostics. BRICS countries represent scale-driven opportunity, with China, India, and Brazil expanding diagnostic capacity while Russia and South Africa face access and infrastructure variability. G7 markets continue to lead in innovation, reimbursement sophistication, and clinical guideline adoption, while NATO member countries collectively emphasize resilient healthcare supply chains and standardized laboratory quality systems.

Key Country Insights in Allergy Diagnostics

The United States leads in allergy diagnostics innovation through advanced laboratory networks, broad use of serum-specific IgE testing, and strong adoption of specialty allergy care, while Canada emphasizes guideline-based care and equitable access through provincial systems. Mexico and Brazil show rising demand through private laboratories and respiratory allergy management, with Brazil offering notable scale in Latin America. The United Kingdom, Germany, France, Italy, and Spain benefit from mature healthcare systems, European allergy research leadership, and growing use of component-resolved diagnostics.

Russia presents a mixed environment shaped by centralized healthcare capacity and regional access gaps. China and India are high-growth markets due to large patient populations, urban air quality concerns, and expanding diagnostic infrastructure, while Japan and South Korea are advanced markets with strong technology adoption and high-quality laboratory standards. Australia demonstrates sophisticated allergy and immunology practice, particularly in food allergy research, pediatric allergy care, and evidence-based testing pathways.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated test menus that align with WAO, EAACI, AAAAI, and national allergy guidelines. Investment should focus on molecular allergy diagnostics, automated immunoassays, pediatric-friendly sampling, and digital interpretation tools that reduce false positives and support better clinical decisions.

Commercial teams should build region-specific access strategies, including reimbursement evidence in mature regions and affordability models in emerging regions. Partnerships with hospitals, reference laboratories, asthma programs, and primary care networks can expand testing adoption, while education for clinicians and patients can reduce misdiagnosis and inappropriate allergen avoidance.

Research Methodology

This executive summary is based on secondary research from verified public-health, regulatory, and clinical sources, including the World Health Organization, World Allergy Organization, CDC, NIH/NIAID, EAACI, AAAAI, FDA, EMA, and peer-reviewed allergy and immunology literature. The analysis emphasizes epidemiology, diagnostic pathways, technology adoption, reimbursement context, and regional healthcare infrastructure.

A structured triangulation approach compares disease-burden indicators, regulatory developments, laboratory adoption patterns, industry activity, and clinical guideline trends. Insights are reviewed for consistency, relevance, and applicability to support executive decision-making in allergy diagnostics.

Conclusion

Allergy diagnostics is moving from a supporting role in allergy care to a strategic enabler of precision medicine, preventive health, and targeted therapy. Rising global allergy prevalence, improved awareness of food and respiratory allergies, and expanding access to immunoassay and molecular testing are creating durable demand for accurate and clinically useful testing.

The next phase of leadership will belong to organizations that combine analytical accuracy, clinical utility, automation, AI-enabled interpretation, and equitable access. Providers that deliver reliable, guideline-aligned, and regionally relevant allergy testing solutions will be best positioned for long-term growth.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Allergy Diagnostics Market, by Test Type

• 7.1. Intradermal Test
• 7.2. Patch Test
• 7.3. Serum-Specific IgE Test
  • 7.3.1. Chemiluminescence Immunoassay
  • 7.3.2. Enzyme-Linked Immunosorbent Assay
  • 7.3.3. Radioallergosorbent Test
• 7.4. Skin Prick Test

8. Allergy Diagnostics Market, by Technology

• 8.1. Chemiluminescence Immunoassay
• 8.2. Enzyme-Linked Immunosorbent Assay
• 8.3. Fluorescent Enzyme Immunoassay
• 8.4. Radioallergosorbent Test

9. Allergy Diagnostics Market, by Sample Type

• 9.1. Blood
• 9.2. Skin
• 9.3. Saliva
• 9.4. Nasal Fluids

10. Allergy Diagnostics Market, by Allergen Type

• 10.1. Contact Allergen
• 10.2. Drug Allergen
• 10.3. Food Allergen
• 10.4. Inhalant Allergen

11. Allergy Diagnostics Market, by End User

• 11.1. Ambulatory Care Centers
• 11.2. Diagnostic Laboratories
• 11.3. Hospitals & Clinics

12. Allergy Diagnostics Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Allergy Diagnostics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Allergy Diagnostics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. ALK-Abello A/S
• 16.3. Allergy Therapeutics PLC
• 16.4. Astra Biotech GmbH
• 16.5. Bausch & Lomb Incorporated
• 16.6. Biomerieux SA
• 16.7. Danaher Corporation
• 16.8. Dr. Fooke-Achterrath Laboratorien GmbH
• 16.9. DST Diagnostische Systeme & Technologien GmbH
• 16.10. Erba Group
• 16.11. Eurofins Scientific
• 16.12. F. Hoffmann-La Roche Ltd
• 16.13. HAL Allergy B.V.
• 16.14. Hitachi, Ltd.
• 16.15. HOB Biotech Group Corp., Ltd.
• 16.16. HollisterStier by Jubilant Life Sciences Limited
• 16.17. HYCOR Biomedical
• 16.18. Lincoln Diagnostics, Inc.
• 16.19. Minaris Medical America, Inc.
• 16.20. Neogen Corporation
• 16.21. Omega Diagnostics Group PLC
• 16.22. Parkway Pantai Ltd.
• 16.23. Quest Diagnostics Incorporated
• 16.24. R-Biopharm AG
• 16.25. Romer Labs Division Holding GmbH by Royal DSM
• 16.26. Siemens AG
• 16.27. Stallergenes Greer International AG
• 16.28. Tecan Trading AG
• 16.29. Thermo Fisher Scientific Inc.